Back

Disparities in the proportion of ticagrelor and prasugrel-eligible patients with NSTE-ACS in a real-world registry

2 September 2024 (12:20 - 12:30)
Organised by: Logo
Congress Presentation Part of: The guardians of clotting: exploring antiplatelet strategies Adjunctive Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

5 More presentations in this session

Presentation thumbnail
Reduction of thrombus burden by cangrelor in ticagrelor-loaded st-elevation myocardial infarction patients with high residual platelet reactivity: the imaging sub-study of the ERMIT randomized trial
Professor F. Beygui (Caen, FR)
Abstract Slides Video
Presentation thumbnail
Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with mild thrombocytopenia undergoing PCI
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention
Doctor W. Dai (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Respective impact of bleeding and ischemic complications of mortality after percutaneous coronary interventions: substudy from the FRANCE-PCI registry
Doctor P. Guedeney (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Complex versus non-complex, should we adjust the antiplatelet strategy to the type of percutaneous coronary intervention? Results from a real world PCI population
Ms E. Woelders (Nijmegen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
The guardians of clotting: exploring antiplatelet strategies
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 12:20 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources